2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Shilpa Gupta, MD, discusses the investigation of enfortumab vedotin with or without additional therapy in cisplatin-ineligible metastatic urothelial carcinoma.
Shilpa Gupta, MD, director, Genitourinary Medical Oncology, Taussig Cancer Institute, co-leader, Genitourinary Oncology Program, Cleveland Clinic, discusses the investigation of enfortumab vedotin-ejfv (Padcev) with or without additional therapy in cisplatin-ineligible metastatic urothelial carcinoma (mUC).
The phase 1/2 EV-103 trial (NCT03288545) is investigating enfortumab vedotin alone and with different combinations of anticancer therapies. In the cisplatin-ineligible patient cohort, the combination of enfortumab vedotin and pembrolizumab (Keytruda) showed remarkable activity and promising overall survival, Gupta explains. Additionally, cohort K randomized patients to enfortumab vedotin vs enfortumab vedotin and pembrolizumab in cisplatin-ineligible patients, Gupta adds.
The combination of enfortumab vedotin and pembrolizumab resulted in beneficial response rates compared with enfortumab vedotin alone; the survival data are not mature and toxicity was higher with the combination therapy, Gupta concludes.